Stefania Capone

Stefania was previously a Senior Scientist at IRBM / Merck and Okairos, where she built strong expertise in molecular and cellular biology and gene-based vaccines. She was a key contributor to the development and clinical validation of the chimpanzee adenovirus technology as a vaccine vector platform for a number of infectious diseases, with particular focus on the characterization of cellular and humoral immune response in preclinical animal models and in human clinical samples.

She also has experience in the design and monitoring of toxicology studies.

Stefania received her degree in Biotechnology at the University of Rome, La Sapienza.

During her 20-year career in the biopharmaceutical environment, she co-authored several publications in high-impact, peer-reviewed journals.